Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy.

Lee JS, Cole SR, Achenbach CJ, Dittmer DP, Richardson DB, Miller WC, Mathews C, Althoff KN, Moore RD, Eron JJ Jr; Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS).

PLoS One. 2018 Jun 5;13(6):e0197665. doi: 10.1371/journal.pone.0197665. eCollection 2018.

2.

Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation.

Lee JS, Cole SR, Richardson DB, Dittmer DP, Miller WC, Moore RD, Kitahata M, Mathews C, Mayer K, Geng E, Achenbach CJ, Eron JJ Jr; Center for AIDS Research Network of Integrated Clinical Systems.

AIDS. 2017 Sep 10;31(14):1989-1997. doi: 10.1097/QAD.0000000000001573.

3.

Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda.

Ssebunya R, Wanyenze RK, Lukolyo H, Mutto M, Kisitu G, Amuge P, Maganda A, Kekitiinwa A.

BMC Infect Dis. 2017 Jun 19;17(1):439. doi: 10.1186/s12879-017-2550-2.

4.

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

Mujugira A, Celum C, Coombs RW, Campbell JD, Ndase P, Ronald A, Were E, Bukusi EA, Mugo N, Kiarie J, Baeten JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):579-84. doi: 10.1097/QAI.0000000000001019.

5.

Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.

Ávila-Ríos S, García-Morales C, Matías-Florentino M, Romero-Mora KA, Tapia-Trejo D, Quiroz-Morales VS, Reyes-Gopar H, Ji H, Sandstrom P, Casillas-Rodríguez J, Sierra-Madero J, León-Juárez EA, Valenzuela-Lara M, Magis-Rodríguez C, Uribe-Zuñiga P, Reyes-Terán G; HIVDR MexNet Group.

Lancet HIV. 2016 Dec;3(12):e579-e591. doi: 10.1016/S2352-3018(16)30119-9. Epub 2016 Sep 14.

PMID:
27658867
6.

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.

Antiretroviral Therapy Cohort Collaboration.

Lancet HIV. 2017 Aug;4(8):e349-e356. doi: 10.1016/S2352-3018(17)30066-8. Epub 2017 May 10.

7.

The effect of HAART on HIV RNA trajectory among treatment-naïve men and women: a segmental Bernoulli/lognormal random effects model with left censoring.

Chu H, Gange SJ, Li X, Hoover DR, Liu C, Chmiel JS, Jacobson LP.

Epidemiology. 2010 Jul;21 Suppl 4:S25-34. doi: 10.1097/EDE.0b013e3181ce9950.

8.

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.

Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E; MOBIDIP study group.

Lancet HIV. 2017 Sep;4(9):e384-e392. doi: 10.1016/S2352-3018(17)30069-3. Epub 2017 May 28.

PMID:
28566227
9.

Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care.

Matthews PE, Le T, Delmar J, Okulicz JF.

Int J STD AIDS. 2015 Nov;26(13):951-9. doi: 10.1177/0956462414563631. Epub 2014 Dec 12.

PMID:
25505041
10.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
11.

Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.

Gianotti N, Galli L, Galizzi N, Ripa M, Andolina A, Nozza S, Spagnuolo V, Poli A, Lazzarin A, Castagna A.

Int J Antimicrob Agents. 2018 Oct;52(4):492-499. doi: 10.1016/j.ijantimicag.2018.07.001. Epub 2018 Sep 13.

PMID:
30009958
12.

HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire.

Hanson DL, Adjé-Touré C, Talla-Nzussouo N, Eby P, Borget MY, Kouadio LY, Celestin BE, Tossou O, Eholie S, Kadio A, Chorba T, Nkengasong JN.

AIDS Res Hum Retroviruses. 2009 May;25(5):489-95. doi: 10.1089/aid.2008.0273.

PMID:
19388820
13.

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.

Stöhr W, Fidler S, McClure M, Weber J, Cooper D, Ramjee G, Kaleebu P, Tambussi G, Schechter M, Babiker A, Phillips RE, Porter K, Frater J.

PLoS One. 2013 Oct 25;8(10):e78287. doi: 10.1371/journal.pone.0078287. eCollection 2013.

14.
15.
16.

Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.

Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H.

Clin Infect Dis. 2013 Nov;57(10):1489-96. doi: 10.1093/cid/cit529. Epub 2013 Aug 14.

PMID:
23946221
17.

How reliable is an undetectable viral load?

Combescure C, Vallier N, Ledergerber B, Cavassini M, Furrer H, Rauch A, Battegay M, Bernasconi E, Vernazza P, Hirschel B; Swiss HIV Cohort Study.

HIV Med. 2009 Sep;10(8):470-6. doi: 10.1111/j.1468-1293.2009.00714.x. Epub 2009 May 6.

18.

Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.

Mulu A, Maier M, Liebert UG.

PLoS One. 2015 Oct 29;10(10):e0141318. doi: 10.1371/journal.pone.0141318. eCollection 2015.

19.
20.

A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada.

Benoit AC, Younger J, Beaver K, Jackson R, Loutfy M, Masching R, Nobis T, Nowgesic E, O'Brien-Teengs D, Whitebird W, Zoccole A, Hull M, Jaworsky D, Rachlis A, Rourke S, Burchell AN, Cooper C, Hogg R, Klein MB, Machouf N, Montaner J, Tsoukas C, Raboud J; Building Bridges; Canadian Observational Cohort Collaboration.

Antivir Ther. 2017;22(4):325-335. doi: 10.3851/IMP3114. Epub 2016 Dec 7.

PMID:
27925609

Supplemental Content

Support Center